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ABSTRACT
Triclosan is a multi-purpose biocide that is used in many personal care products,
including antibacterial handsoaps and toothpastes. The wide usage of triclosan fosters its
dispersal into the environment which might contribute to the ability of microorganisms
to become resistant to triclosan in addition to certain other biocides and clinical
antibiotics.
The aim of this study was to evaluate whether long-term exposure of two strains
of Staphylococcus epidermidis to subinhibitory concentrations oftriclosan would select
for resistant mutants, and whether their ability to form polysaccharide biofilms lends to
this resistance. This study also aimed to dete1mine whether a mutation in the triclosan
target was responsible for resistance, and to determine whether these mutants could
exhibit cross-resistance to chlorhexidine and clinical antibiotics. In addition, efflux
capability was assessed as a presumable resistance mechanism.
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PREFACE
The figures and literature cited in this thesis were written according to the fo1mat of the
Journal of Bacteriology, published by the American Society for Microbiology, to which it
will be submitted for publication.
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INTRODUCTION
Staphylococci

The Scottish physician Sir Alexander Ogston identified the bacterial genus
Staphylococcus in 1880, as it was one of the primary causative agents associated with
wound infections (37). Sir Alexander named Staphylococcus after he observed its
characteristic grape-like clusters under a microscope (37). Staphylococci are Grampositive cocci that are non-flagellate, non-motile, non-spore forming, facultative
anaerobes that produce the enzyme catalase (1 ).
Staphylococcus is commonly divided into two distinct groups: those that produce
the enzyme coagulase, and those that do not (1 ). Jacques Loeb first reported coagulase
activity in 1904 (22). Loeb's method of observation is now referred to as the tube
coagulase test, which led to the fmiher examination and characterization of
Staphylococcus aureus in 1934 (22). Coagulase is an enzyme that binds to prothrombin,
and initiates the polymerization of fibrin, which results in the coagulation of blood
plasma (1 ). Staphylococcus aureus is a coagulase-positive organism relevant to the field
of medicine (1 ). The medical relevance of Staphylococcus aureus is largely due to its
multiple virulence factors including toxic shock syndrome toxin-1, alpha-toxin, emetic
pyrogenic superantigens, and enterotoxins (I) Staphylococcus aureus was isolated in
1884 by German scientist Anton Rosenbach (36). Rosenbach also distinguished between
Staphylococcus aureus and Staphylococcus epidermidis by describing two pigmented
colony types (36). The pigments led to his appropriately proposed nomenclature:
Staphylococcus aureus so named for its golden color, and Staphylococcus a/bus for its
white color. Staphylococcus albus is now known as Staphylococcus epidermidis (36).
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Coagulase-Negative Staphylococci
Members of the genus Staphylococcus that do not produce coagulase are referred
to as coagulase-negative staphylococci (CoNS). CoNS are often used in the food
processing industry as sta1ier cultures for fermented food products such as fermented
sausages (22). Such organisms include Staphylococcus xylosus, Staphylococcus carnosus,
Staphylococcus s11cci1111s, and Staphylococcus equorum (22).
Other CoNS are found naturally living in the mucous membranes and on the
surfaces of warm-blooded birds and animals, including humans (21). Coagulase-negative
staphylococci are often considered to be beneficial as they are used in the food processing
industry, and because they exist as normal floral symbionts. However, CoNS are
opportunistic pathogens, especially in immunocompromised, long-term hospitalized, and
critically ill patients (22).
Common CoNS that have the ability to produce infection in humans include
Staphylococcus saprophyticus and Staphylococcus epidermidis. Staphylococcus
saprophyticus is a common cause of urinary tract infections in sexually active females
(1). Staphylococcus epidermidis, which is most often associated with medical prosthetic

devices, is the most common CoNS of concern (1 ). Infection can occur upon implantation
of a device by either the seeding of the device during a prior bacteremia or by gaining
access to the lumina of catheters and shunts (1 ).

Pathogenesis of Staphylococcus epidermidis
Staphylococcus epidermidis, which is the most frequently isolated species of
CoNS, is the leading cause of infections related to prosthetic medical devices (49). The

ability of Staphylococcus epidermic/is to cause infection is due to virulence factors such
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as delta-toxin (47). Staphylococcus epidermidis is also frequently able to resist the action
of antibiotics due to its ability to form viscous extracellular polysaccharide biofilms on
surfaces (27). Multiple factors facilitate the initial adherence of Staphylococcus
epidermidis to prosthetic devices, including macromolecular components in body fluids
such as blood, urine, saliva, and mucus (6). Other nonspecific physiochemical variables
for adherence include Van der Waals forces, surface tension, temperature, and
electrostatic interactions (12). Staphylococcus epidermidis also has surface proteins
including SSP-1 and SSP-2, which function in the adherence of the cells onto polystyrene
surfaces (46). The surface protein function is largely due to their organization into
fimbria-like structures (46). Once adherence has occurred, the proliferation stage
commences, where the production of extracellular polysaccharides and polysaccharide
intercellular adhesin (PIA) is upregulated cementing the cells to each other and to the
surface (6). PIA is a linear 13-1,6-linked glucosaminoglycan which is synthesized by
enzymes encoded by the ica operon (33). PIA provides extra adhesion and encases the
entire bacterial population, acting as a shield against the host defense systems and
externally administered antimicrobial agents (33).
A mature biofilm is comprised of several layers and reveals groups of
microcolonies, which are separated by fluid-filled channels (33). These channels are
thought to facilitate distribution of nutrients and oxygen throughout the biofilm in
addition to the removal of metabolic waste (17).
Detachment of cells from a biofilm is the combined effect of cell viability, growth
patterns, and shear stress (51). Staphylococcus epidermidis secretes delta-toxin, which

lyses erythrocytes in mammalian hosts, acts as a detergent during biofilm detachment
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(47). The accessory gene regulator (agr) quorum sensing system is also thought to
function in biofilm detachment by dowmegulating surface protein expression and
upregulating exoenzyme and toxin expression (3 7). The agr quorum sensing system has
been observed as being expressed only by the outer, most exposed, layers of the biofilm
(48).
Clinical problems that have arisen due to the fonnation ofbiofilms on indwelling
medical devices are largely due to the fact they are frequent inhabitants of the surface of
human skin, mucous membranes, ear canals, and anterior nares. In the past 50 years,

Staphylococcus epidermidis has become a significant opportunistic pathogen due to its
ability to resist certain antibiotics, especially in hospital patients who have received
vascular grafts, heart valves, coronary stents, and fracture-fixation implants (10). The
ability of Staphylococcus epidermidis to resist multiple antibiotics is largely due not only
to the ability of the organism to form biofilms, but also to the extensive use of
antimicrobials and disinfectants, which exerts selective pressure (33). This selective
pressure can potentially lead to the evolution of a multi-drug resistance phenotype.

Antibiotic Resistance Mechanisms
The ability of staphylococci to resist antibiotics continues to escalate as one of the
major complications in medical microbiology. Misuse of antibiotics including using them
to treat colds, flu, or other viral infections, causes the antibiotics to become less effective
against the bacterial agents they were originally intended to treat (31 ). Less than 3% of

Staphylococcus aureus strains were resistant to penicillin G when it was first introduced

(1). Over 90% of Staphylococcus aureus strains are now resistant to penicillin G (1).
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This phenomenon illuminates the potential for rapid bacterial evolution resulting in
antibiotic resistance. Staphylococcus epidermidis, being an abundant inhabitant of human
skin, is constantly exposed to multiple fmms of selection pressure such as over the
counter antibacterial products. This form of oppo1iunity combined with its bountiful
genetic flexibility makes Staphylococcus epidermidis the perfect contender for the
development of resistance. As antibiotic resistance continues to emerge as one of the
greatest public health concerns on a global scale, one of the aims of the scientific
community is to identify factors that are essential for the virulence of pathogens (29).
There are several known mechanisms used by bacteria to resist antibiotics. Some
bacteria produce enzymes that alter the antibacterial agent so it can no longer bind to its
target molecule (1 ). Some bacteria have evolved the ability to alter the molecule targeted
by a particular antibiotic (1 ). Cetiain bacteria, namely Gram-negative organisms, alter
porins, which leads to a decreased uptake of the drug (1). Other organisms use molecular
efflux pumps to export antimicrobials out of the cell (1). These efflux pumps have been
attributed to the ability of cells to eliminate more than one antibiotic (9).
The resistance mechanisms mentioned above could be evolved independently or
acquired on mobile genetic elements via conjugation, transduction, or transfonnation,
which often facilitates the incorporation of multiple resistance genes into the genome or
plasmids within the host cell (45).
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Enoyl-Acyl Carrier Protein Reductase (Fahl) and Triclosan
Antibiotics seek to inhibit pathways required for a bacterium to survive, yielding
either a bactericidal or bacteriostatic effect. An impo1tant pathway used by

Staphylococcus epidermidis is the assembly of fatty acids via the expression of the enoylacyl carrier proteinreductase gene (Jab]) (18). The assembly of fatty acids brings
together two-carbon units in a cyclic sequence of reactions (18). Fabl is used to catalyze
the final step in each cycle (18). Fab 1 also plays a regulatory role in determining the rate
of fatty acid synthesis. Inhibitors of this step in the fatty acid synthesis pathway such as
hexachlorophene and triclosan are thus effective antibacterial agents (Fig. 1) (18).
2-Hydroxyphenylethers make up a group of compounds exhibiting a broad
antimicrobial activity spectrnm (7). Of these compounds, 2,4,4' -trichloro-2' hydroxydiphenyl ether, more commonly referred to as triclosan (Fig. 2), is the most
potent and widely used (7). Triclosan was first introduced in 1965 and has been shown to
be very stable, as it has the ability to resist degradation in both dilute acidic and alkaline
solutions (50). Triclosan is a multi-purpose biocide and has been used for more than 30
years in many personal care products, including antibacterial hand soaps, antiseptics,
cutting boards, facial cleansers, lotions, and toothpastes (15). This wide and long-term
use not only exposes human normal floral organisms to the biocide, but fosters the
dispersal of the biocide into the envir01m1ent, which, as the present study indicated, might
explain the ability of microorganisms to become less susceptible to antibiotics and
biocides, including triclosan, via either intrinsic or acquired mechanistic adaptations upon
exposure (42).

It was once thought the mode of action of triclosan was nonspecific cellular
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membrane disruption (18). However, it is now known triclosan works by inhibiting
enoyl-acyl carrier protein reductase (Fabl) in a broad spectrum ofboth Gram-positive
and Gram-negative organisms which use this enzyme in the elongation cycle ofbacterial
fatty acid biosynthesis (13). Triclosan, which exhibits the hallmarks of a slow-binding
inhibitor, inhibits Fabl by forming a stable, non-covalent, Fab1-NAD+-triclosanternary
complex, leading to complete inhibition of bacterial growth and replication (18) (Fig. 1).

Triclosan Resistance
Despite its potent mode of action, there are some bacteria that remain resistant to
triclosan. Some of the various mechanisms of conferred triclosan resistance include:
decreased influx/membrane pe1meability, increased target expression, the expression of
highly efficient efflux pumps that function to rid the cell oftriclosan, target mutation, the
production of an enoyl reductase enzyme having a low affinity for triclosan, and the
expression of a triclosan degrading enzyme (39, 50). For example, Pseudomonas

ae111gi11osa expresses Fabl but is still resistant to triclosan due to expression of the
MexAB-OprM efflux system (7).

Staphylococcus aureus usually is susceptible to triclosan. Triclosan has thus been
used in an effort to control the spread ofmethicillin-resistant Staphylococcus aureus
(MRSA) in hospitals (24). A study conducted in 2003 suggested the wide usage of
triclosan would not select for triclosan resistant MRSA; however, it was found that some
MRSA clones might not be as susceptible to triclosan as normal strains (2). Other

laboratory studies have shown mutations infabl and their overexpression correlate to
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the decreased susceptibility of Escherichia coli and Staphylococcus aureus to triclosan

(13).
A recent study showed repeated Staphylococcus aureus exposure to subinhibitory
triclosan concentrations resulted in increased resistance to triclosan (24). Triclosan
exposure also led to the attenuation ofbiofilm forming ability, hemolysis, DNase, and
coagulase activities (24). These data suggest an increased triclosan resistance could also
be associated with reduced pathogenicity (24). Latimer et. al., 2012 used a concentration
of0.0029% triclosan, which is a concentration several orders of magnitude lower than the
concentration used in most commercial products. The study presented in this thesis used
triclosan concentrations up to 1.5% to simulate the actual effects of using products
containing therapeutic concentrations of triclosan as an active ingredient.

Correlation of Triclosan Resistance to Clinical Antibiotic Resistance
In addition to the wide use oftriclosan selecting for resistance, one of the major
concerns of the overuse oftriclosan is its ability to cause resistance to other antimicrobial
agents, including traditional, clinical antibiotics. It is thought inappropriate administration
of antibiotics can select for more generalized resistance (31 ). This rationale has been
demonstrated in several bacterial strains including Pseudomonas ae111ginosa and
Escherichia coli (7). It has also been demonstrated in Salmonella enterica and
Mycobacterium smegmatis, in which resistance to triclosan has also been shown to lead
to resistance to the antibiotic isoniazid (4, 7). The prevalence of Staphylococcus
epidermidis, its constant exposure to triclosan, inherent genetic flexibility, and the
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multiple demonstrations oftriclosan-mediated cross-resistance to traditional antibiotics
in different organisms, suggests Staphylococcus epidermidis could demonstrate a
profound ability to resist triclosan, which might help mediate cross-resistance to
antibiotics with multiple modes of action. To test this rationale, the present study used six
antibiotics to represent several of the broad classes of antibiotics, based on mode of
action. These were ampicillin and vancomycin, which affect cell wall synthesis,
azithromycin, which acts on the 50S ribosomal subunit to interfere with protein synthesis,
gentamicin and tetracycline, which also interfere with protein synthesis, but by acting on
the 30S ribosomal subunit, and ciprofloxacin, which targets DNA gyrase and
topoisomerase IV interfering with nucleic acid synthesis. These antibiotics are chemically
classified as B-lactams, glycopeptides, macrolides, aminoglycosides, tetracyclines, and
fluoroquinolones respectively (1 ).

Chlorhexidine
N-(4-chlorophenyl)-1-3-(6-{N-[3-(4 chlorophenyl)
carbamimidamidomethanimidoyl] amino} hexyl) carbamimidamidomethanimidamide,
more commonly known as chlorhexidine, is an antimicrobial compound often used in
such products as surgical scrnbs, topical anti-infective agents, and oral rinses (11 ).
Chlorhexidine is effective against a broad range of Gram-positive and Gram-negative
organisms and is thought to function by destroying the integrity of the cell membrane and
precipitating the cytoplasm (11 ). This mechanism makes a chlorhexidine resistance
phenotype highly unlikely; however, development of stable resistance to chlorhexidine
has been observed in strains of Pseudomonas stutzeri after being exposed to increasing

concentrations of the agent (44). These resistant strains have also shown reduced
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sensitivity to antibiotics and biocides such as triclosan (5). Resistance is thought to be
associated with cell envelope alterations or the presence of constitutive degradative
enzymes (5).

Project Overview
This project sought to determine whether exposure of two different strains of

Staphylococcus epidermidis to the biocide triclosan could lead to an increased minimum
inhibitory concentration. This study also sought to detennine whether an increased
resistance was made more efficient by the ability of the organism to form a
polysaccharide biofilm. This project investigated whether triclosan resistance in

Staphylococcus epidermidis could be mediated by Jab] mutation or an increased efflux
capability.
With respect to triclosan, this study also aimed to determine whether long-term
exposure to subinhibitory triclosan could lead to an increased resistance to the
disinfectant chlorhexidine or clinically administered antibiotics.

MATERIALS AND METHODS
Bacterial Cultures
Two Staphylococcus epidermidis strains were donated by Dr. Greg Somerville's
lab at the University ofNebraska. These strains are SE1457 and SE1457 l'l.ica. SE1457
has been genetically altered to overexpress the intercellular adhesion (ica) operon, while
the ica operon has been removed from SE1457 l'l.ica to have discemable biofilm positive
and negative strains, respectively.

Establishing the Triclosan Minimum Inhibitory Concentration
Unless stated otherwise, all incubations in this work were at 37 °C. Triclosan
stock was prepared by dissolving 0.75 g oftriclosan in 5.0 mL of95% ethanol. This is
15% triclosan, which is l00X the normal therapeutic concentration in personal care
products, which is 0.15%. This stock solution was diluted by adding 50 µL of the l00X
stock to 5.0 mL oftryptic soy broth (TSB). A ten-fold serial dilution scheme was then
used to dilute the triclosan to a series from 0.15% to 0.0000015%. Fifty microliters of
overnight cultures of both strains of Staphylococcus epidermidis were introduced into 5.0
mL of each of the serially diluted triclosan-containing broths. The strains were incubated
for 24 hours. The minimum inhibitory concentration (MIC) was defined as the lowest
concentration of triclosan in which there was no turbidity.
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Establishing the Chlorhexidine Minimum Inhibitory Concentration
A 20% w/v aqueous solution of chlorhexidine gluconate (Alfa Aesar, Ward Hall,
MA) was diluted in TSB to 2.0%, which is the typical concentration used in oral rinses
and scrnbs. A ten-fold serial dilution scheme was used to dilute the chlorhexidine to a
series from 2.0% to 0.000002%. The serially diluted tubes were each inoculated with 50
µL of overnight TSB cultures of either SE1457 having been passed in TSB for 70 days,
SE1457 having been exposed to subinhibitory triclosan for 70 days, SE1457Llica having
been passed in TSB for 70 days, or SE1457 Llica having been exposed to subinhibitory
triclosan for 70 days. The cultures were incubated for 24 hours, and the MIC of each
strain was defined as the lowest concentration of disinfectant at which there was no
turbidity.

Cell maintenance
Once the MICs oftriclosan were established for each strain, one group of both
strains was exposed to a subinhibitory concentration oftriclosan for 14 days, while
another group of each strain was grown in TSB in the absence of triclosan. In this case,
the subinhibitory concentration was 1/10 of the MIC. Each group of cells was incubated
for 24 hours, and then 50 uL of culture were passed into 5.0 mL of the appropriate fresh
growth medium after each 24-hour incubation period. The triclosan MICs were
reevaluated at the end of every 14-day period via the serial dilution method mentioned
previously. Whenever an MIC increase was observed, the subinhibitory concentration to
which the cells were exposed was increased accordingly such that the cells continued to
be exposed to a 1/10 subinhibitory concentration.
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Frozen stocks of the unexposed cells and the triclosan exposed cells were
prepared each time an increase in MIC was observed. To do this, a sterile 60% glycerol
solution was prepared by diluting glycerol with deionized water. The stocks were then
prepared by combining 750 µL of overnight culture and 250 µL of the 60% glycerol
solution in 1.5 mL microcentrifuge tubes. The resulting stocks were frozen at -80 °C.

Polymerase Chain Reaction
The enoyl-acyl carrier protein reductase gene (fabl) was amplified by the
polymerase chain reaction (PCR). Primers were designed from the sequence of

Staphylococcus epidermidisfabl deposited in GenBank. The primers used were
FablF (5' AGTATCGCATTTGGCGTCGCT 3') and
FablR (5'GCGTTTTAACGGCGCTCTCGC 3'). GoTaq PCR Core System II, which
contains the components used in the PCR, was purchased from Promega Corporation
(Madison, WI). The following PCR components were combined in a 0.5 mL
microcentrifuge tube: 5.0 µL of25 mM magnesium chloride solution, 10 µL of5X green
GoTaq flexi buffer, 1.0 µL of PCR nucleotide mix, containing 10 mM of each of the
dNTPs, 1.5 µL ofFablF primer, 1.5 µL ofFablRprimer, 0.5 µL ofGoTaqpolymerase,
20.5 µL of nuclease-free water, and 10 µL of DNA template from Staphylococcus

epidermidis. Template DNA was genomic DNA prepared by boiling the cultures for five
minutes. The PCR was allowed to occur in a thermocycler with the following conditions:
95 °C for three minutes, followed by 40 cycles of 95 °C for 45 seconds, 55 °C for one
minute, and 72 °C for one minute. The final elongation cycle was allowed to occur at 72
°C for 10 minutes. PCR amplification ofthefabl gene was conducted on both the

triclosan-exposed cells and the unexposed cells. PCR product was confirmed by using
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1.5% agarose gel electrophoresis.

DNA Sequencing and Alignment

The PCR products were submitted to GeneWiz (South Plainfield, NJ) for direct
sequencing by using the same primers as those used for the PCR. The resulting sequences
were translated to peptide sequences by using EMBOSS Transeq Sequence Translation
tools from EMBL-EBI. Both the DNA sequences and the peptide sequences were aligned
by using EMBOSS Needle Pairwise Sequence Alignment tools from EMBL-EBI.

Kirby-Bauer Disc Diffusion Assay

The Kirby-Bauer disc diffusion assay was used to evaluate any differences in
antibiotic resistance that might have occurred in both the unexposed and the triclosan
exposed strains. The assay was conducted according to the manufacturer's instructions
(BD, Franklin Lakes, NJ). Briefly, the bacterial strains were incubated in tubes containing
TSB for 24 hours. The strains were then standardized in a spectrophotometer by using a
0.5 McFarland Standard at a wavelength of 595 nm. Bacterial lawns were then streaked
onto Mueller-Hinton agar by using sterile cotton swabs so as to completely cover the
Petri plates. Antibiotic-embedded filter paper discs were placed on the Petri plates by
using an antibiotic disc dispenser. The antibiotics used were: ampicillin (10 µg),
azithromycin (15 µg), ciprofloxacin (5 µg), gentamicin (10 µg), tetracycline (30 µg), and
vancomycin (30 µg). Diameters of zones of inhibition were measured with a millimeter
ruler.
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Etest
The Etest was conducted on the triclosan-exposed and unexposed bacteria by
following the instrnctions provided by the manufacturer (bioMerieux, Durham, NC).
Briefly, the bacterial strains were incubated in tubes containing TSB for 24 hours. The
strains were then standardized in a spectrophotometer by using a 0.5 McFarland Standard
at a wavelength of 595 nm. Bacterial lawns were streaked onto Mueller Hinton agar, by
using sterile cotton swabs. One E-strip was used per Petri plate and the results were read
according to the Etest reading guide found in the Etest pack insert provided by the
manufacturer. Antibiotics used in the Etest were the same as those used in the KirbyBauer disc diffusion assay.

Efflux Assay
A quantitative efflux-mediated multi-drug resistance assay was used according to
Martins et. al., (2010) to detem1ine whether subinhibitory triclosan exposure influenced
the overexpression of efflux systems. Ethidium bromide (Sigma-Aldrich, St. Louis, MO)
was prepared in distilled water at a stock concentration of 50 mg/Land was protected
from light by storing it in bottles wrapped in aluminum foil. Tryptic soy agar plates
containing the following concentrations of ethidium bromide were prepared: 0.0, 0.5, 1.0,
1.5, 2.0, and 2.5 mg/L. Twenty groups of cells, representing each of the five increases in
triclosan MIC and their corresponding unexposed strains, were grown for 24 hours in 5.0
mL ofTSB and standardized to an optical density of0.6 at a 600 nm wavelength.

Pseudomonas aeruginosa (ATCC 24783) and Escherichia coli (ATCC 25922) were
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used as positive and negative controls, respectively, for efflux ability.
Bacterial samples were streaked with a sterile swab in a cartwheel pattern on tryptic soy
agar (TSA) plates containing various concentrations of ethidium bromide. The plates
were incubated for 18 hours, and observed under ultraviolet light and photographed. The
minimal concentration of ethidium bromide that led to fluorescence was recorded.

RESULTS AND DISCUSSI ON
Effects of Triclosan Exposure

In this study, passage of Staphylococcus epidermidis SE1457 and SE1457 l'.ica in
subinhibitory concentrations oftriclosan for 70 days resulted in an increase in the MIC of
triclosan. For both strains, the initial triclosan MIC was 0.00015% and the final MIC was
1.5%. Hence, after 70 days of exposure to a 1/10-subinhibitory concentration of triclosan,
the exposed cells became 10,000 times more resistant to triclosan than their
corresponding unexposed strains (Fig. 3). The triclosan MIC increased at the same rate in
both biofihn-positive and biofilm-negative strains. This suggested that the presence of an
ica operon does not contribute to an increased ability to resist triclosan. The
concentration of triclosan found in most personal care products is 0.15% meaning
subinhibitory exposure resulted in resistance to the typical therapeutic dose of triclosan.

Chlorhexid ine

The minimum inhibitory concentration of chlorhexidine was 0.00002% on all
strains of Staphylococcus epidermic/is used in this study. Thus, neither the ability to form
a biofilm nor an increased ability to resist triclosan, regardless of extended exposure time,
had any effect on the ability of the organism to resist chlorhexidine. These results further
support the rationale that an increased resistance to chlorhexidine is unlikely due to the
fact chlorhexidine is thought to have multiple targets (11 ).
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DNA Sequencing and Alignment
One proposed mechanism of triclosan resistance in Staphylococcus aureus is
changes in the penneabili ty of the cell wall could prevent triclosan from reaching its
target site (43). Other studies have shown that/ab] mutation can lead to the development
of triclosan resistance in organisms such as Escherichia coli and Staphylococcus aureus
(16). It has also been demonstrated that afabl mutation is required for triclosan
resistance and that the altered/ab ] must be overexpressed at levels three- to fivefold
higher than the level of expression in triclosan-sensitive strains (13).
In this study, sequencing of the Jab] gene, amplified from the triclosan resistant
Staphylococcus epidermic/is SE1457 strain and the corresponding unexposed strain,
showed a point mutation at position 235 in the triclosan exposed strain (Fig. 4). This
mutation codes for an amino acid change from alanine to valine at position 95 in the
protein sequence (Fig. 5). The Ala-95 in the unexposed strain has been shown to be part
of the active site region of the Fab1-NAD+-triclosan ternary complex (19). The 4-chloro
substituent oftriclosan accepts a hydrogen bond from the amide backbone of Ala-95 (19).
These data suggested afabl mutation could lead to the development oftriclosan
resistance in Staphylococcus epidennidi s as a result of long-tenn subinhibitory triclosan
exposure.
The difference between alanine and valine is that they contain a methyl side chain
and an isopropyl side chain respectively. This indicates that the isopropyl side chain in
valine blocks the ability of the 4-chloro substituent oftriclosan from accepting the
hydrogen bond from the amino acid backbone. This could interfere with the Fabl-NAD+-
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triclosan ternary complex, thereby preventing the triclosan from functioning to inhibit
bacterial fatty acid elongation.

Kirby-Bauer Disc Diffusion Assay and Etest (Ampicillin)
In addition to triclosan exposure leading to an increased triclosan MIC, a series of
Kirby-Bauer disc diffusion assays showed that cells, having evolved the ability to resist
triclosan, also evolved an increased resistance to ampicillin whereas the unexposed
strains did not. Etests confirmed the results of the Kirby-Bauer assays.
The ampicillin zone of inhibition increased from 25 mm to 30 mm in the
unexposed SE1457 strain between 0 days and 70 days of passage (Fig. 6). The MIC
increased from 0.016 µg/mL to 0.5 µg/mL (Fig. 7). The changes in the unexposed
SE1457 strain was most likely due to a random error in the standardization of the cells.
The ampicillin zone of inhibition decreased in diameter from 25 mm to 6 mm in the
triclosan exposed SE1457 strain between 0 days and 70 days oftriclosan exposure (Fig.
6). The MIC increased from 0.016 µg/mL to 1.0 µg/mL (Fig. 7). According to the Zone
Diameter Interpretive Chart from BD, staphylococci are considered to be resistant to
ampicillin if the zone diameter around the ampicillin impregnated disc is <S28mm; hence,
the triclosan-exposed SE1457 strains with triclosan MICs of0.15% and 1.5% both
evolved resistance to ampicillin.
The ampicillin zone of inhibition increased in diameter from 25 mm to 30 mm in
the unexposed SE1457L'lica strain between 0 days and 70 days of passage (Fig. 6). The
MIC increased from 0.016 µg/mL to 0.023 µg/mL (Fig. 7). These changes were most
likely due to a random error in the standardization of the cells. The ampicillin zone of
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inhibition decreased in diameter from 25 mm to 6 mm in the triclosan exposed
SE1457/'l.ica strain between 0 days and 70 days ofsubinhibitorytriclosan exposure (Fig.
6). The MIC increased from 0.016 µg/mL to 0.75 µg/mL (Fig. 7). Hence the triclosan
exposed SE1457 /'l.ica strains with triclosan MI Cs of 0.15% and 1.5% both evolved
resistance to ampicillin.
Ampicillin is known to interfere with cell wall synthesis by binding to
penicillin-binding proteins inside the cell wall (34). A recent study showed that the
exposure of Staphylococcus aureus to sub lethal concentrations of penicillin caused two
cell wall proteins to shift from the peripheral wall to the septum, which was most likely
due to an antibiotic mediated increase of free anchoring sites at the septum (52). In a
similar manner, it is possible triclosan exposure could caused the shifting of the
penicillin-binding proteins, therefore accounting for this ampicillin resistance.

Kirby-Bauer Disc Diffusion Assay and Etest (Tetracycline)
In addition to triclosan exposure leading to an increased triclosan MIC and
ampicillin resistance, a series of Kirby-Bauer disc diffusion assays showed that cells,
having evolved the ability to resist triclosan, also evolved an increased resistance to
tetracycline whereas the unexposed strains did not. Etests confirmed the results of the
Kirby-Bauer assays.
The tetracycline zone of inhibition decreased in diameter from 30 mm to 26 mm
in the unexposed SE1457 strain between 0 days and 70 days of passage (Fig. 8). The MIC
decreased from 0.5 µg/mL to 0.094 µg/mL (Fig. 9). These changes were most likely due
to random errorin the standardization of the cells. The tetracycline zone of inhibition
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decreased in diameter from 30 mm to 10 mm in the triclosan exposed SE1457 strain
between 0 days and 70 days of subinhibitory triclosan exposure (Fig. 8). The MIC
increased from 0.5 ug/mL to 32 µg/mL (Fig. 9). According to the Zone Diameter Chart
from BD, staphylococci are considered to be resistant to tetracycline if the zone diameter
around the tetracycline impregnated disc is <14 mm, hence the triclosan exposed SE1457
strains with triclosan MICs of0.15% and 1.5% both evolved resistance to tetracycline.
There were no changes in the tetracycline zones of inhibition in the unexposed
SE1457 l'iica strain between 0 days and 70 days of passage (Fig. 8). The MIC decreased
from 0.5 µg/mL to 0.125 µg/mL (Fig. 9). This change was most likely due to random
error in the standardization of the cells. The tetracycline zone of inhibition decreased in
diameter from 30 mm to 7 mm in the triclosan exposed SE1457 l'iica strain between 0
days and 70 days of subinhibitory triclosan exposure (Fig. 8). The MIC increased from
0.5 µg/mL to 96 µg/mL (Fig. 9). Hence, the triclosan exposed SE1457 l'iica strains with
triclosan MICs of0.15% and 1.5% both evolved resistance to tetracycline.
Tetracyclines inhibit the synthesis of protein by binding to the 30S ribosomal
subunit and blocking the attachment of aminoacyl-tRNA to the acceptor site of the
mRNA ribosome complex, thus preventing the introduction of new amino acids to the
nascent polypeptide chain (1 ).
Two tetracycline resistance mechanisms have been identified in staphylococci.
They are the acquisition plasmids carrying tetK and tetL genes, which result in active
efflux, and tetM or tetO determinants carried on either the chromosome or transposons,
which mediate ribosomal protection (41). MGE mediated resistance is unlikely due to the
fact these experiments were carried out in pure culture in a closed system. A more likely
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resistance mechanism is the production of ribosomal protection proteins due to a
chromosomal mutation. Possibly the cell wall has been altered in a way that has
decreased its pe1meability.

Kirby-Bauer Assay and Etest (Azithromycin, Gentamicin, and Vancomycin)
With respect to resistance, there was no difference in the zones of inhibition or
MICs of azithromycin, gentamicin, or vancomycin on either the triclosan exposed cells or
the unexposed cells (Fig. 10 to 13). These data suggest long-term exposure to
subinhibitory triclosan does not influence an increased resistance to these antibiotics.

Kirby-Bauer Disc Diffusion Assay and Etest (Ciprofloxacin)
The unexposed strain of SE1457 i'.ica displayed an increased resistance to
ciprofloxacin after being passed in TSB for 70 days. The results ofa Kirby-Bauer disc
diffusion assay showed a decrease in the diameter of zone of inhibition around the disc
impregnated with ciprofloxacin from 30 mm to 15 mm (Fig. 10). The MIC increased
from 0.064 µg/mL to 3.0 ug/mL (Fig. 11). According to the Zone Diameter Interpretive
Chart from BD, staphylococci are considered to be resistant to ciprofloxacin if the zone
diameter around the ciprofloxacin impregnated disc is :Sl 5 mm, hence the unexposed
SE1457i'.ica strain of Staphylococcus epidermic/is evolved resistance to ciprofloxacin in
the absence of selection pressure. This is likely dne to a copying error during DNA
replication. None of the other strains exhibited resistance to ciprofloxacin.
There are two broad mechanisms of fluoroquinolone resistance, which occur as a
result of chromosomal mutation (20). The mechanisms are alterations that limit the

permeation of the drug to the target and alterations in the target enzymes of the drug
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(20). In Gram-positive organisms, the target enzyme is topoisomerase IV (35). Although
plasmid-mediated ciprofloxacin resistance has been observed, the data presented in this
thesis suggested a chromosomal mutation was the most likely mechanism for resistance
since the strains in this study were grown in pure culture. The data also shed light on the
inherent genetic flexibility of Staphylococcus epidermidis.

Efflux Assay
The efflux-assay uses ethidium bromide, which is a universal efflux pump
substrate (30). Ethidium bromide functions by binding with DNA and intercalating
between its hydrophobic base pairs. This intercalation causes the DNA to stretch,
removing water molecules from the ethidium cation. The resulting distortion of the
double helix interferes with DNA replication, transcription, and DNA repair. This
dehydration resulted in an increased fluorescence of the ethidium and the cell. The assay
is based on the rationale that there is a maximum ethidium bromide concentration that
can be effectively extruded by cells (30). Any concentration greater than this maximum
will be retained by the cell and will lead to the detection of fluorescence when exposed to
ultraviolet light (30). The smallest concentration of ethidium bromide that leads to
fluorescence is the highest concentration of ethidium bromide that the bacteria can
exclude (30).
In addition to providing a method of ranking bacterial strains according to efflux
capability, this assay also allows for the observation of ethidium bromide resistance.

In this study, the assays showed no evidence of an increased efflux capability and the
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bacterial strains were, therefore, not quantitatively ranked. The assay did, however, show
a correlation between increased triclosan MIC and the ability of Staphylococcus
epidermidis to grow in increasing concentrations of ethidium bromide (Fig. 14 to 17).

All of the unexposed SE1457 strains were inhibited by 2.0 mg/L of ethidium
bromide (Fig. 14). The triclosan exposed SE1457 strains, having been exposed to
subinhibitory concentrations oftriclosan for 56 days and 70 days, grew in 2.5 mg/L of
ethidium bromide (Fig. 15). All of the unexposed SE 14571"ica strains were inhibited by
2.0 mg/L of ethidium bromide (Fig. 16). The triclosan exposed strains of SE14571"ica,
having been exposed to subinhibitory triclosan concentrations for 42 days, 56 days, and
70 days, grew in 2.5 mg/L of ethidium bromide (Fig. 17). All of the strains that grew in
2.5 mg/L of ethidium bromide demonstrated growth in 4.0 mg/L of ethidium bromide
(figures not shown).
At physiological ionic strength, ethidium is very sensitive to the composition and
sequence of polymeric nucleic acids (26). Ethidium has a 100-fold higher affinity to poly
d(AT)-poly d(AT) as compared to poly d(A)-poly d(T) (26). It also exhibits a preference
for the alternating purine-pyrimidine tract of poly d(GC)-poly d(CG) as compared to poly
d(G)-poly d(C) (26). Additionally, ethidium exhibits a 10-fold higher affinity to poly
d(G)-d(C) over poly d(A)-d(T) (26). Luedtke et. al., (2003) and the data from this thesis
suggest there might have been cln·omosomal mutations profound enough to lower the
binding affinity of ethidium bromide to the DNA of the bacterial strains exposed to
higher concentrations oftriclosan, thereby decreasing the susceptibility of those strains to
the ethidium bromide.

CONCLUSIONS
A study conducted in 1990 in which 12 populations of Escherichia coli were
allowed to evolve for 2,000 generations showed an increase of about 37% in mean fitness
(25). Eighteen thousand generations later, two of those populations were examined for
the parallel evolution of gene-expression profiles when compared to the original ancestor
population (8). The expression of 59 genes changed significantly in both populations in
the same direction relative to the ancestor (8). This profusion of change, despite the lack
of selection pressure, substantiates the rationale that selection pressure might lead to a
pattern of parallel evolution even more expeditious than demonstrated in this study.
The fact that two triclosan-resistant strains of Staphylococcus epidermidis
exhibited resistance to ampicillin and tetracycline as well as a decreased susceptibility to
ethidium bromide, despite each of these antibacterial agents having different modes of
action, could be indicative of several phenomena.
One potential phenomenon is a mechanism leading to an increased cell wall
thickness relative to increased selection pressure. This phenomenon has been observed in
association with vancomycin resistance in Staphylococcus epidermic/is (14). Another
potential explanation is triclosan exposure caused diminished cell wall permeability,
which could be the result of multiple factors, including the shifting of cell wall proteins,
which has been shown to occur in Staphylococcus aureus in association with sublethal
ampicillin exposure (52). Mutation in thefabl gene was most likely the cause oftriclosan
resistance, and some other cln·omosomal mutation is most likely the cause of resistance to
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the other antibacterial agents since all of the experiments in this study were carried out
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in pure culture.
This demonstration ofa 10,000-fold increase in triclosan resistance in
Staphylococcus epidermidis over 70 days, due to the application of selection pressure,
demonstrates the antimicrobial resistance problem associated with the overuse and
misuse of antibacterial agents. The results also provide evidence that distribution of overthe-counter antimicrobials into the environment can induce resistance to that particular
antimicrobial in addition to ce1iain clinical antibiotics. This thesis supported the rationale
that triclosan as well as other disinfectants should only be used circumspectly where clear
health benefits can be discerned (24).
Further studies should continue to investigate, identify, and understand other
potential antibiotic resistance mechanisms. It is also necessary to understand the link
between triclosan resistance and this newly acquired multi-drug resistance phenotype.
Several proposed resistance mechanisms have been discussed; however, it is also possible
that resistances mechanisms that have not yet been reported are the causes of this multidrug resistance phenotype.
The relatively recent antibiotic-as-beneficial-signal hypothesis suggests
antibiotics in nature evolved as a communication method between unrelated microbial
species, but, if introduced to a bacterial population at a high enough concentration, can
cause death (40). Work in the lab of Julian Davies over the last 15 years has indicated
antibiotics made by microbes perfo1m multiple functions and that the molecules are more
often a means of communication than of inhibition (32).
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The microbial detection of low concentrations of antibiotics might be
interpreted as a warning for fnture increased concentrations, which could allow the
organism to respond in a manner that reduces susceptibility (40). Pseudomonas

aeruginosa, for example, fmms a biofilm as a response to subinhibitory tetracycline
concentrations, thereby reducing its exposure to future antibiotics (40). This study shows

Staphylococcus epidermidis has a similar inherent ability to respond to triclosan, thereby
initiating the observed change in the Fabl sequence.
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FIG. 1. The triclosan mode of action is to target enoyl-acyl carrier protein
reductase (Fab 1), the final enzyme in the fatty acid elongation cycle, by using
NADH to reduce the double bond ofFabl (Adapted from Patel et. al., 2008).
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FIG. 2. Molecular structure of 2,4,4' -trichloro-2' -hydroxydiphenyl ether
(triclosan) (From Margaretha et. al., 2001),

36

37

Triclosan MIC: SE1457
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FIG. 3. MIC oftriclosan on (A) unexposed SE1457 compared to triclosanexposed SE1457, and (B) unexposed SE1457 L\.ica compared to triclosan-exposed
SE1457 L\.ica.
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FIG. 4. Nucleotide alignment from EMBOSS for SE1457 fabl from the unexposed strain
(Sbjct) and triclosan-exposed strain after 70 days of exposure (Query) generated from the
forward and reverse primers. The point mutation of position 235 is indicated by a circle.
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FIG. 5. Partial protein alignment results from blastx for SE1457 Fabl sequences from the
unexposed strain (Sbjct) and triclosan-exposed strain after 70 days of exposure (Query).
The mutation of alanine (A) to valine (V) at position 95 is indicated by a circle.
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Kirby-Bauer Assay (Ampicillin): SE1457
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FIG. 6. Ampicillin zone of inhibition of (A) unexposed SE1457 compared to
triclosan-exposed SE1457, and (B) unexposed SE1457i'.ica compared to
triclosan-exposed SE1457 i'.ica.
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FIG. 7. MIC ofampicillin on (A) unexposed SE1457 compared to
triclosan-exposed SE1457, and (B) unexposed SE1457tica compared to triclosanexposed SE1457 tica as determine by Etests.
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Kirby-Bauer Assay (Tetracycline): SE1457
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FIG. 8. Tetracycline zone of inhibition of(A) unexposed SE1457 compared to
triclosan-exposed SE1457, and (B) unexposed SE1457i'.ica compared to
triclosan-exposed SE1457 i'.ica.
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Etest (Tetracycline): SE1457
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FIG. 9. MIC of tetracycline on (A) unexposed SE1457 compared to
triclosan-exposed SE1457, and (B) Unexposed SE1457i'iica compared to
triclosan-exposed SE 1457 i'iica as determined by Etests.
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Kirby-Bauer Assay (Azithromycin &
Ciprofloxacin): SE1457
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FIG. 10. Azithromycin and ciprofloxacin zones of inhibition of (A) unexposed
SE1457 compared to triclosan-exposed SE1457, and (B) unexposed SE1457~ica
compared to triclosan-exposed SE1457~ica.
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FIG. 11. MIC of azithromycin and ciprofloxacin on (A) unexposed SEl 457
compared to triclosan-exposed SE1457, and (B) unexposed SE1457~ica
compared to triclosan-exposed SE1457 ~ica as dete1mined by Etests.
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l{irby-Bauer Assay (Gentamicin &
Vancomycin): SE1457
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FIG. 12. Gentamicin and vancomycin zones of inhibition of(A) unexposed
SE1457 compared to triclosan-exposed SE1457, and (B) unexposed SE1457Liica
compared to triclosan-exposed SE1457 Liica.
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FIG. 14. Evaluation of efflux activity of unexposed SE1457 strains. In a
counterclockwise fashion, the strains are Pseudomonas aeruginosa (PA),

Staphylococcus epidermidis passed in TSB for 14, 28, 42, 56, and 70 days, and
Escherichia coli (EC).
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FIG. 15. Evaluation of efflux activity oftriclosan-exposed SE1457 strains. In a
counterclockwise fashion, the strains are Pseudomonas ae111gi11osa (PA),

Staphylococcus epidermidis exposed to subinhibitory triclosan for 14, 28, 42, 56, and 70
days, and Escherichia coli (EC).
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FIG. 16. Evaluation of efflux activity of unexposed SE1457i'.ica. In a counterclockwise
fashion, the strains are Pseudomonas aeruginosa (PA), Staphylococcus epidermidis
passed in TSB for 14, 28, 42, 56, and 70 days, and Escherichia coli (EC).
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FIG. 17. Evaluation of efflux activity oftriclosan-exposed SE1457~ica strains. In a
counterclockwise fashion, the strains are Pseudomonas ae111ginosa (PA), Staphylococcus

epidermic/is exposed to subinhibitory triclosan concentrations for 14, 28, 42, 56, and 70
days, and Escherichia coli (EC).
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Appendix A: Molecular structures of the cell wall inhibitor antibiotics, (A) ampicillin,
which is a semisynthetic penicillin thought to function by inhibiting the final step in
bacterial cell wall synthesis leading to the lyses of the cell, and (B) vancomycin, which is
a glycopeptide that also inhibits cell wall synthesis (1, 11).
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Appendix B: Molecular structures of (A) ciprofloxacin, which is a fluoroquinolone that
inhibits bacterial nucleic acid synthesis by inhibiting bacterial DNA-gyrase and
topoisomerase IV in Gram-negative and Gram-positive organisms respectively, and (B)
azitluomycin, which is a macrolide antibiotic that binds to 23S rRNA in the 50S subunit
blocking translocation (1, 11).
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Appendix C: Molecular structures of (A) gentamicin, which is an aminoglycoside that
directly inhibits protein synthesis by binding to the 30S ribosomal subunit, and causing
the misreading of mRNA, and (B) tetracycline, which binds to the 30S ribosomal subunit,
and inhibits the binding of aminoacyl-tRNA molecules to the ribosome (1, 11 ).
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Appendix D: Molecular structure of ethidium bromide, which is a universal efflux pump
substrate, and can also interfere with DNA replication (30).
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Appendix E: Molecular structure of chlorhexidine, which is a disinfectant and topical
anti-infective agent. It is often used in mouthwashes to prevent oral plaque (11 ).
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